Journal
AMERICAN JOURNAL OF CANCER RESEARCH
Volume 11, Issue 10, Pages 5027-+Publisher
E-CENTURY PUBLISHING CORP
Keywords
Helicobacter pylori; antibiotics; phenotypic resistance; genotypic resistance
Categories
Funding
- Scientific Research Program of Shanghai Municipal Science and Technology Commission [18441906900]
- Shanghai Zhangjiang Hi-Tech Park Manage-ment Committee RAMP
- D Public Service Platform Capacity Enhancement Project: Shanghai Zhangjiang Biobank [2016-07]
- Jiangsu Provincial Key Research and Development Program [BE2019614]
- Shanghai Municipal Health Commission Advanced Appropriate Technology Promotion Project [2019SY067]
- Postdoctoral Research Foundation of China [2020M670068ZX]
Ask authors/readers for more resources
Helicobacter pylori antibiotic resistance is a serious concern in China, where personalized therapies based on genotype testing could partially replace traditional antibiotic susceptibility testing. Continuous monitoring and personalized treatments remain necessary for effective management of H. pylori infections in China.
Helicobacter pylori antibiotic resistance is a serious concern in China, where it severely influences treatment for H. pylori infection. To overcome this, it is essential to apply personalized therapies based on local or individual data on antibiotic-resistant phenotypes or genotypes. We conducted a large-scale multi-center study with a retrospective cross-sectional observational design to investigate the antibiotic-resistant phenotypes and genotypes of H. pylori in China. Strains were isolated from the gastric biopsy samples of H. pylori-infected patients from five different regions in China. The strains were tested for antibiotic-resistant phenotypes and genotypes, and the agreement between the two was assessed. In total, 4242 H. pylori strains were isolated and cultured, with an 84.43% success rate. The primary and secondary antibiotic resistance rates of H. pylori were 37.00% and 76.93% for clarithromycin, 34.21% and 61.58% for levofloxacin, 2.20% and 6.12% for amoxicillin, 1.61% and 3.11% for furazolidone, 1.18% and 3.31% for tetracycline, and 87.87% and 93.48% for metronidazole, respectively. The dual-resistance patterns for metronidazole/clarithromycin, metronidazole/levofloxacin, and clarithromycin/levofloxacin were 43.6%, 38.4%, and 26.1%, respectively. Clarithromycin- and levofloxacin-resistant H. pylori phenotypes and genotypes showed satisfactory agreement. Based on these findings, clarithromycin- and levofloxacin-resistant genotype testing could partially replace traditional antibiotic susceptibility testing in China. Continuous monitoring and personalized treatments based on individual and local H. pylori antibiotic-resistance data remain necessary.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available